IGC Pharma, Inc. Common Stock
Key Metrics
Market Snapshot
About
IGC Pharma, Inc. (IGC) is a clinical-stage biopharmaceutical company based in Potomac, Maryland, best known for its development of therapeutic candidates for Alzheimer's disease and related neurodegenerative disorders.
The company's primary focus is on addressing the symptoms of Alzheimer's, particularly agitation in dementia. Its lead investigational drug, IGC-AD1, is currently in a Phase II clinical trial for this condition. Beyond this lead candidate, IGC Pharma has additional pre-clinical stage programs designed to treat Alzheimer's disease. These include TGR-63 and IGC-M3, which represent earlier-stage research efforts. The company also utilizes artificial intelligence to support its therapeutic development pipeline.
In addition to its drug development work, the company is active in digital health through the development of MINT-AD, an artificial intelligence-driven clinical assistant intended for use by healthcare providers. IGC Pharma operates primarily in the United States and Colombia. The company was originally incorporated in 2005 and underwent a significant rebranding, changing its name from India Globalization Capital, Inc. to IGC Pharma, Inc. in March 2023 to better reflect its concentrated focus on pharmaceuticals.